rifampin and Lung-Abscess

The association sarcoidosis-lung abscess due to emerging microorganisms-mycetoma has prompted the authors to report the above clinical case which is interesting in view of the rarity of the disease and of its infective complications. The authors also review the literature on the subject.

Topics: Bronchoalveolar Lavage Fluid; Ceftazidime; Fluconazole; Humans; Lung Abscess; Male; Middle Aged; Mycetoma; Radiography, Thoracic; Rifampin; Sarcoidosis; Tomography, X-Ray Computed

Corynebacterium (Rhodococcus) equi is becoming increasingly significant as a cause of bronchopneumonia and lung abscessation in foals. The organism can survive within macrophages and may thus escape normal pulmonary defence mechanisms, particularly in immunocompromised animals. The disease has hitherto been associated with mortality rates as high as 80 per cent, partly as a result of inappropriate therapy. The selection of lipid-soluble antibiotics capable of intracellular penetration is critical for the successful treatment of C equi lung abscesses. A combination of two such antibiotics, erythromycin (25 mg/kg three times daily) and rifampicin (5 mg/kg twice daily) has been used on foals since 1981. Most of these animals had radiographic evidence of extensive lung abscessation, and in all cases the presence of C equi was confirmed on culture of tracheal aspirates. The duration of therapy ranged from four to nine weeks. Mild gastritis and diarrhoea were occasionally noted, but never such as to require termination of the therapy. No other adverse side effects were encountered. The success rate, as judged by a return to normal of chest radiographs and plasma fibrinogen concentrations, has exceeded 80 per cent.

Topics: Actinomycetales Infections; Animals; Drug Therapy, Combination; Erythromycin; Horse Diseases; Horses; Lung Abscess; Rhodococcus; Rifampin

The objectives of the present study were to determine the relative efficacy of tulathromycin, azithromycin, or azithromycin with rifampin for the treatment of pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi. Foals with ultrasonographic evidence of pulmonary abscesses (abscess score 8.0-15 cm; n=120) were randomly allocated in four equal treatment groups: (1) tulathromycin intramuscularly; (2) azithromycin monotherapy, orally; (3) azithromycin with rifampin, orally; (4) saline intramuscularly as a placebo. Physical examination and thoracic ultrasonography were performed by individuals unaware of treatment group assignment. Foals that worsened were removed from the study. The proportion of foals that recovered without the need for a change in therapy was significantly higher for foals treated with azithromycin (29 of 30) or azithromycin with rifampin (28 of 30) than for foals treated with a placebo (20 of 30). Additionally, azithromycin or azithromycin with rifampin resulted in a significantly faster decrease in the number of abscesses and abscess score compared with a placebo. The proportion of foals treated with tulathromycin that recovered (27 of 30) was not significantly different from that of foals treated with a placebo. Azithromycin alone or in combination with rifampin was beneficial in the study population.

Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Disaccharides; Double-Blind Method; Drug Therapy, Combination; Endemic Diseases; Germany; Heterocyclic Compounds; Horse Diseases; Horses; Lung Abscess; Pneumonia, Bacterial; Rhodococcus equi; Rifampin; Severity of Illness Index; Treatment Outcome

Mass antimicrobial treatment of foals with small ultrasonographic pulmonary lesions is common on farms with endemic disease caused by Rhodococcus equi. The objectives of this study were to compare the relative efficacy of three antimicrobial protocols for the treatment of pulmonary abscesses on a farm with endemic infections caused by R. equi and to determine the frequency of spontaneous resolution of subclinical pulmonary lesions. Foals with ultrasonographic evidence of pulmonary abscesses ≥ 1.0 cm in diameter (n=128) were randomly allocated to one of four equal treatment groups. Animals with respiratory distress or severe pulmonary lesions were excluded from the study. Treatment groups consisted of: (1) tulathromycin intramuscularly; (2) azithromycin monotherapy orally; (3) azithromycin in combination with rifampin orally; and (4) glucose orally as a placebo. Physical examination, thoracic ultrasonography and white blood cell (WBC) counts were performed weekly by individuals unaware of treatment group assignment. Foals that worsened were removed from the study and treated with azithromycin and rifampin. Overall, 14/32 (43.8%) foals in the placebo group recovered without the need for therapy. The proportion of foals that responded to the initial therapy, the duration of therapy, the kinetics of ultrasonographic lesion resolution, the proportion of foals that had to be removed from the study and the number of days to removal from the study did not differ significantly between treatment groups. The study showed that many foals with pulmonary abscesses recover without antimicrobial therapy. Moreover, treatment of sub-clinically affected foals with antimicrobial agents did not significantly hasten recovery.

Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Disaccharides; Double-Blind Method; Drug Therapy, Combination; Endemic Diseases; Female; Heterocyclic Compounds; Horse Diseases; Horses; Lung Abscess; Male; Rhodococcus equi; Rifampin; Time Factors; Treatment Failure

Topics: Actinomycetales Infections; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Diagnosis, Differential; Drug Therapy, Combination; Fertilizers; Humans; Imipenem; Immunocompromised Host; Leukemia, Myelomonocytic, Chronic; Lung Abscess; Lung Neoplasms; Male; Manure; Opportunistic Infections; Rhodococcus equi; Rifampin; Shock, Septic; Tomography, X-Ray Computed

A 26-year-old pregnant woman who was an intravenous drug user (IDU) was admitted to our hospital for the treatment of tricuspid valve infective endocarditis (IE) and lung abscesses due to methicillin-resistant Staphylococcus aureus (MRSA). We started to treat her with vancomycin (VCM) alone and then in combination with rifampicin (RFP), but her condition did not improve. Then we added sulfamethoxazole/trimethoprim (SMZ/TMP) to VCM and RFP. After that, she improved rapidly. In Japan, there are very few reports about tricuspid valve IE caused by MRSA in IDUs. This case suggests that the combination of VCM, RFP, and SMZ/TMP may be effective for the treatment of severe MRSA infections.

Topics: Adult; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Lung Abscess; Methicillin-Resistant Staphylococcus aureus; Pregnancy; Pregnancy Complications, Infectious; Pulmonary Embolism; Rifampin; Staphylococcal Infections; Substance Abuse, Intravenous; Tricuspid Valve; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin

In this report, a renal transplant recipient with Rhodococcus lung abscess is described. A high clinical suspicion and appropriate combination antibiotic therapy obviated the need for surgical intervention and was associated with a good clinical outcome. The optimal regimen of combination antibiotic therapy is discussed.

Topics: Actinomycetales Infections; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Kidney Transplantation; Lung Abscess; Male; Meropenem; Radiography; Rhodococcus equi; Rifampin; Sirolimus; Thienamycins; Treatment Outcome; Vancomycin

Tulathromycin is a new injectable macrolide antibiotic used for the treatment of pulmonary diseases of swine and cattle. In this study, 37 foals with sonographic evidence of lung abscesses were treated with tulathromycin (2.5mg/kg intramuscularly [IM] once weekly, group 1) and 33 foals (group 2) with a combination of azithromycin (10mg/kg per os [PO] once daily for the first seven days of therapy, thereafter every other day) and rifampin (10mg/kg PO twice daily). The bacterial aetiological agent was not determined. The foals were only mildly sick and the median number of pulmonary abscesses was 1.4 (group 1) and 1.6 (group 2). Thirty foals in each group were treated without modifying therapy protocols until all clinical signs of disease had subsided. Tulathromycin was administered for a mean of 53 days, and azithromycin/rifampin for 42 days. The following side effects were associated with tulathromycin (279 IM injections): self-limiting diarrhoea in 11 foals; elevated temperature in six foals, and swellings at the injection site in 12 foals. This study provides some evidence that tulathromycin is well tolerated and appears promising for the treatment of pulmonary abscesses in foals.

Topics: Administration, Oral; Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Disaccharides; Drug Therapy, Combination; Heterocyclic Compounds; Horse Diseases; Horses; Injections, Intramuscular; Lung Abscess; Random Allocation; Rifampin; Time Factors; Treatment Outcome

The antimicrobial susceptibilities of 30 Rhodococcus equi isolates obtained from 30 patients between 1993 and 2001 in northern Thailand were investigated. The MICs showed a tendency toward resistance to various antibiotics but sensitivity to imipenem, minocycline, vancomycin, and teicoplanin (MICs, /=64 micro g/ml) to rifampin. PCR amplification and DNA sequencing of the rpoB gene and molecular typing by pulsed-field gel electrophoresis (PFGE) were performed for eight R. equi isolates from eight AIDS patients with pneumonia or lung abscess caused by R. equi between 1998 and 2001, including one low- and three high-level rifampin-resistant isolates. As a result, two high-level rifampin-resistant strains with PFGE pattern A had a Ser531Trp (Escherichia coli numbering) mutation, and one high-level rifampin-resistant strain with PFGE pattern B had a His526Tyr mutation, whereas one low-level rifampin-resistant strain with PFGE pattern C had a Ser509Pro mutation. Four rifampin-susceptible strains with PFGE patterns D and E showed an absence of mutation in the rpoB region. Our results indicate the presence of several types of rifampin-resistant R. equi strains among AIDS patients in northern Thailand.

Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Animals; Antibiotics, Antitubercular; DNA-Directed RNA Polymerases; Drug Resistance, Bacterial; Female; Humans; Lung Abscess; Male; Microbial Sensitivity Tests; Mutation; Pneumonia, Bacterial; Rhodococcus equi; Rifampin; Thailand

Topics: Actinomycetales Infections; Adult; Ciprofloxacin; Drug Resistance, Microbial; HIV Infections; Humans; Lung Abscess; Male; Rhodococcus equi; Rifampin

Of nine patients with Legionnaires' disease, seven were receiving corticosteroids, and all nine had serious underlying diseases. Direct immunofluorescent examination of respiratory secretions, including sputum and transtracheal aspirates, showed the Legionnaires' disease (LD) bacterium in five of seven patients who seroconverted and in a sixth patient with a single elevated titer to the LD bacterium. All nine patients received erythromycin therapy, and five survived. Two patients showed persistence of their infection after receiving 2 weeks of erythromycin therapy, and two patients developed pulmonary abscesses. These cases of Legionnaires' disease show the occurrence of pulmonary abscesses, the possibility of relapse after giving only 2 weeks of erythromycin therapy, and the utility of direct immunofluorescence for early diagnosis.

Topics: Adrenal Cortex Hormones; Adult; Aged; Erythromycin; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Legionnaires' Disease; Lung Abscess; Male; Middle Aged; Recurrence; Rifampin; Transplantation, Homologous

Topics: Adult; Humans; Lung Abscess; Male; Rifampin

Topics: Adult; Bronchiectasis; Bronchitis; Bronchopneumonia; Humans; Lung Abscess; Male; Middle Aged; Rifampin

Topics: Acute Disease; Bronchitis; Bronchopneumonia; Humans; Lung Abscess; Pneumonia, Pneumococcal; Rifampin

Topics: Adolescent; Adult; Bacteria; Bronchitis; Bronchopneumonia; Child; Female; Humans; Lung Abscess; Male; Middle Aged; Pleuropneumonia; Pneumonia; Rifampin